Aethlon Medical, Inc.
AEMD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $153 | $155 | $84 | $0 |
| Gross Profit | -$153 | -$155 | -$84 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $294 | $524 | $1,328 | $240 |
| G&A Expenses | $0 | $1,211,390 | $0 | $1,088 |
| SG&A Expenses | $1,063 | $1,211,390 | $592 | $1,815 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $726 |
| Other Operating Expenses | $0 | -$1,210,277 | $0 | -$240 |
| Operating Expenses | $1,357 | $1,637 | $1,920 | $1,815 |
| Operating Income | -$1,510 | -$1,792 | -$2,004 | -$1,815 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $23 | $31 | -$4,251 | $60 |
| Pre-Tax Income | -$1,487 | -$1,762 | -$6,255 | -$1,755 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,487 | -$1,762 | -$6,255 | -$1,755 |
| % Margin | – | – | – | – |
| EPS | -3.74 | -8.5 | -40.1 | -8.6 |
| % Growth | 56% | 78.8% | -366.3% | – |
| EPS Diluted | -3.74 | -8.5 | -40.1 | -8.6 |
| Weighted Avg Shares Out | 398 | 208 | 156 | 204 |
| Weighted Avg Shares Out Dil | 398 | 208 | 156 | 204 |
| Supplemental Information | – | – | – | – |
| Interest Income | $23 | $36 | $94 | $60 |
| Interest Expense | – | $0 | $10 | $0 |
| Depreciation & Amortization | $153 | $155 | $84 | $84 |
| EBITDA | -$1,334 | -$1,607 | -$6,161 | -$1,731 |
| % Margin | – | – | – | – |